Eye health innovation – the first FDA-approved contact lenses for myopia management
81% of all eye care professionals state that myopia, nearsightedness, is one of the largest problems currently affecting children’s vision. MiSight may empower eye doctors with a solution to this problem. Recently, the FDA granted approval to Coopervision for MiSight 1-Day, the first contact lenses meant to slow myopia progression in children aged 8 to 12.
Not only does myopia progression cause the need to buy new, stronger eyeglasses for kids all the time, but it also puts kids at an increased risk for developing other eye problems in the future, such as retinal detachment and glaucoma. MiSight contacts can help curb this risk!
Benefits of MiSight
- Easy for kids to wear and handle
- 1-Day disposable contacts require virtually no maintenance
- Appropriate for children from age 8
- Corrects distance vision effectively
- Helps to slow the progression of myopia, so vision prescriptions stop changing continuously
The MiSight® 1 day lens is clinically proven to slow the progression of myopia when initially prescribed for children 8-12 years old*. It serves as the cornerstone of a comprehensive myopia management approach that we expect to launch in the U.S. in Spring 2020.
MiSight 1 day contact lenses were clinically validated in a multi-year comprehensive study that enrolled children between 8 and 12.
Over three years, MiSight reduced myopia progression by 59%, versus a single vision 1 day lens.1
The clinical study of MiSight 1 day lenses was the first to demonstrate sustained reduction in myopia progression with a soft contact lense over a three-year period.